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Psoriasis is one of the most common T cell–mediated autoimmune diseases in humans. 
Although a role for the innate immune system in driving the autoimmune T cell cascade has 
been proposed, its nature remains elusive. We show that plasmacytoid predendritic cells 
(PDCs), the natural interferon (IFN)-
 
 
 
–producing cells, infiltrate the skin of psoriatic 
patients and become activated to produce IFN-
 
 
 
 early during disease formation. In a 
xenograft model of human psoriasis, we demonstrate that blocking IFN-
 
 
 
 signaling or 
inhibiting the ability of PDCs to produce IFN-
 
 
 
 prevented the T cell–dependent development 
of psoriasis. Furthermore, IFN-
 
 
 
 reconstitution experiments demonstrated that PDC-derived 
IFN-
 
 
 
 is essential to drive the development of psoriasis in vivo. These findings uncover a 
novel innate immune pathway for triggering a common human autoimmune disease and 
suggest that PDCs and PDC-derived IFN-
 
 
 
 represent potential early targets for the 
treatment of psoriasis.
 
Psoriasis is the most common autoimmune
disease of the human skin, affecting 
 
 
 
2% of
the population worldwide (1). Similar to Crohn’s
disease and rheumatoid arthritis, psoriasis re-
sults from an overt self-perpetuating activation
of autoimmune T cells (2–4). Through the
secretion of Th1 cytokines, these T cells con-
tribute to the epidermal hyperproliferation in
genetically predisposed individuals. The initial
onset of the lesions is commonly followed by
chronic relapses of the disease triggered by in-
fections, mechanical stress, and drugs (5). Al-
though it is still unclear how these environ-
mental factors drive the pathogenic T cell
cascade, it has been suggested that innate im-
mune pathways may provide the missing link
(6, 7).
Plasmacytoid pre-DCs (PDCs) are a rare
cell population in the peripheral blood and sec-
ondary lymphoid organs characterized by plasma
cell–like morphology and a unique surface
phenotype (8). PDCs represent key effectors in
innate antiviral immunity because of their unique
capacity to secrete large amounts of IFN-
 
 
 
 in
response to viruses (9, 10). Upon viral stimula-
tion, PDCs differentiate into DCs (11, 12) and/
or induce an IFN-
 
 
 
–dependent maturation of
bystander myeloid DCs with the ability to drive
Th1 responses (13), thus providing a unique
link between innate and adaptive antiviral immu-
nity. During homeostasis, PDCs are encountered
exclusively in the blood and lymphoid organs;
however, viral infection leads to an active re-
cruitment of PDCs from the blood into periph-
eral sites of infection (14). Recent studies have
shown that PDCs may also accumulate in pe-
ripheral tissues during certain noninfectious in-
flammatory disorders (15–18), including psoriasis
(17, 19), although a functional relevance has
not been demonstrated.
There are three scientific observations that
suggest a role for IFN-
 
 
 
 in psoriasis. First, pso-
riatic skin lesions demonstrate an activated
IFN-
 
 
 
 signaling pathway (20–23). Second,
continuous excessive IFN-
 
 
 
/
 
 
 
 signaling in
IFN regulatory factor (IRF)-2
 
 
 
/
 
 
 
 mice causes
an inflammatory skin disease resembling psoria-
sis (24). Finally, treatment of psoriasis patients
with recombinant IFN-
 
 
 
 for unrelated condi-
tions (e.g., viral infections or tumors) can exac-
erbate psoriasis (25–28). We therefore hypoth-
esized that IFN-
 
 
 
 produced by PDCs may
contribute to the pathogenesis of psoriasis.
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We show that PDCs infiltrate the normal-appearing skin
of psoriatic patients and become activated to produce IFN-
 
 
 
early during the development psoriatic skin lesions. Fur-
thermore, we demonstrate that PDC-derived IFN-
 
 
 
 is es-
sential in driving the local activation and expansion of
pathogenic T cells leading to the development of psoriatic
skin lesions. Thus, activation of PDCs to produce IFN-
 
 
 
 in
the skin of psoriatic patients represents a key innate immune
pathway to initiate the autoimmune T cell cascade leading
to psoriasis.
Figure 1. PDC infiltration in the skin of psoriasis patients. (a) Immu-
nohistochemical analysis of BDCA-2 expression in psoriatic plaque 
lesions. A representative staining (n   8) at 400  is shown. Bar, 40  m. 
(b) CLSM of psoriatic plaque lesions stained for BDCA-2 (green), CD123 
(red), and CD3 (blue). A representative analysis shows PDCs costaining 
for BDCA-2 and CD123 (yellow), T cells staining for CD3 (blue), and 
CD123 single-positive endothelial cells (*, red). Dashed lines indicate the 
border between the epidermis (top) and dermis (bottom). (c and d) Flow 
cytometric quantification of PDCs in dermal single cell suspensions iso-
lated from psoriatic plaque lesions, uninvolved skin, normal skin, and 
peripheral blood of psoriatic patients and healthy individuals according 
to their BDCA-2  CD123high phenotype. Representative flow cytometry 
analyses are shown in panel c and the percentages of BDCA-2  
CD123high PDCs are indicated in the plots. The results of multiple donors 
are plotted in panel d. Horizontal bars represent the mean. 
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RESULTS
PDC accumulation in the skin of psoriasis patients
 
To assess the presence of PDCs in psoriatic skin, we performed
immunohistochemistry and confocal laser scan microscopy us-
ing an antibody specific for human blood PDCs (anti–BDCA-2;
reference 29). High numbers of PDCs were found throughout
the T cell–rich infiltrate in the dermis of primary psoriatic
plaque lesions (Fig. 1, a and b). In contrast, PDCs were com-
pletely absent in the normal skin of healthy donors or the
inflamed skin of atopic dermatitis patients (Fig. S1, available
at http://www.jem.org/cgi/content/full/jem.20050500/DC1),
as previously reported (18). We confirmed the specificity of
BDCA-2 for PDCs in psoriatic skin by flow cytometry analysis
of dermal single cell suspensions, showing that BDCA-2
 
 
 
PDCs expressed high levels of CD123 (Fig. 1 c), were positive
for MHC class II and CD4, lacked both lineage markers (CD3,
CD14, CD20, and CD56) and myeloid markers (CD11b and
CD11c), and displayed characteristic plasmacytoid morphology
(reference 30; Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20050500/DC1). Interestingly, we observed
an increased frequency of PDCs in both plaque lesions (mean,
8.6%; range, 3–14% of total dermal mononuclear cells) and the
nearby uninvolved (normal appearing) skin of psoriatic patients
(mean, 3.1%; range, 1–5.6%) compared with the skin of
healthy individuals (consistently 
 
 
 
0.03%; Fig. 1 c). In addition,
we found a decrease of PDCs in the peripheral blood of psori-
asis patients (mean, 0.18%; range, 0.08–0.26%) compared with
the peripheral blood of healthy individuals (mean, 0.32%;
range, 0.18–0.65%; Fig. 1, c and d), suggesting that the accu-
mulation of PDCs in psoriatic skin resulted from an active re-
distribution of PDCs from the blood into the skin, similar to a
phenomenon observed in systemic lupus erythematosus (SLE;
reference 31).
 
PDCs are activated in psoriatic skin lesions
 
Given that PDCs are present in the peripheral blood, the
uninvolved skin, and the plaque lesions of psoriatic patients,
we sought to investigate the activation profile of PDCs in
these three compartments by examining their expression lev-
els of costimulatory molecules CD80 and CD86 and matura-
tion marker CD83. Peripheral blood PDCs of psoriatic pa-
tients exhibited a typical resting phenotype of PDCs, lacking
the expression of CD80 and CD83 and expressing low levels
of CD86 (Fig. 2). A similar resting phenotype was observed
in PDCs accumulating in the uninvolved skin of psoriasis pa-
tients (Fig. 2). In contrast, PDCs in psoriatic plaque lesions
showed expression of CD80 and CD83 and enhanced levels
of CD86 when compared with PDCs in uninvolved skin
and peripheral blood (Fig. 2). These data indicate that PDCs
are activated locally in psoriatic skin lesions.
 
IFN-
 
 
 
 is expressed early and transiently during the 
development of psoriasis
 
Because PDCs have the unique ability to produce large
amounts of IFN-
 
 
 
 on activation, we sought to analyze IFN-
 
 
 
expression in psoriatic skin. Initial investigations did not
reveal substantial up-regulation of IFN-
 
 
 
 mRNA in primary
psoriatic plaque lesions compared with the normal skin of
healthy individuals. However, psoriatic plaque lesions, but
not uninvolved skin or normal skin, consistently demon-
strated a significantly increased expression of IRF-7, an IFN-
 
 
 
–inducible gene (P
 
   
 
0.0001; references 32 and 33; Fig.
3 a), and the presence of MxA protein, a marker for IFN-
 
 
 
activity (references 34 and 35; Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20050500/DC1). Given
the presence of an IFN-
 
 
 
 signature in the absence of detect-
able levels of the IFN-
 
 
 
 cytokine, we questioned whether
IFN-
 
 
 
 had been produced earlier during the development of
the psoriatic plaque lesion. To analyze the early stages of
psoriasis development, we took advantage of a xenograft
model of human psoriasis developed in our laboratory in
which the uninvolved (prepsoriatic) skin of psoriasis patients
spontaneously converts into a full-fledged psoriatic skin
lesion on transplantion onto AGR
 
 
 
/
 
 
 
 mice within 35 d
(36). This model system depends on the activation and pro-
liferation of autoimmune T cells derived from the engrafted
prepsoriatic skin (36) and allows temporal analyses of psoria-
sis development. Human IFN-
 
 
 
 mRNA expression levels in
skin grafts increased as early as day 7 after transplantation and
reached a peak at day 14 before rapidly declining (Fig. 3 b,
top left), whereas its signature, detected by increased IRF-7
expression levels, persisted throughout the 35-d develop-
ment of the psoriatic plaque (Fig. 3 b, top right). It is note-
worthy that skin grafts of control mice transplanted with the
normal skin of healthy donors did not develop an IFN-
 
 
 
 sig-
Figure 2. Local activation of PDCs in psoriatic plaque lesions. Flow 
cytometry analysis of CD86, CD80, and CD83 expression by BDCA-2  
CD123  PDCs in dermal single cell suspensions of plaque lesions, unin-
volved skin, and peripheral blood derived from the same psoriasis patient. 
Open histograms represent staining of DC activation markers; closed his-
tograms represent isotype control. Data are representative of three inde-
pendent experiments. Differences in the percentages of CD86high, CD80 , 
and CD83  expression on PDCs between plaque lesions and uninvolved 
skin (P   0.007, P   0.02, and P   0.005, respectively) and between 
plaque lesions and peripheral blood (P   0.006, P   0.02, and P   0.005, 
respectively) were significant. 
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nature within 35 d (unpublished data). The early induction
of IFN-
 
 
 
 in engrafted prepsoriatic skin was paralleled by the
activation and expansion of pathogenic T cells (Fig. 3 b, bot-
tom). In contrast, the psoriatic phenotype, defined by the
typical epidermal hyperplasia involving a thickening of the
epidermis (acanthosis), as well as the elongation of the epi-
dermal rete ridges (reflected in the papillomatosis index),
showed delayed kinetics starting at day 21 after transplanta-
tion and reaching complete development at day 35 (Fig. 3 b,
bottom). These data indicate that IFN-
 
 
 
 expression is an
early and transient event during the development of the pso-
riatic phenotype and precedes a completely activated epider-
mal compartment. During this early wave of IFN-
 
 
 
 secre-
tion, MxA expression was confined to cells of the dermal
compartment and involvement of cells of the epidermal
compartment occurred at later time points (after day 14 of
engraftment; unpublished data), indicating that IFN-
 
 
 
 origi-
nates in cells of the dermal compartment.
 
PDCs are the principal IFN-
 
 
 
–producing cells 
in developing psoriasis
 
To identify the cellular source of IFN-
 
 
 
, we sampled the
margin zone of spreading psoriatic plaque lesions as a surro-
gate for early developmental disease stages in psoriasis pa-
tients (37). Intracellular staining of dermal single cell suspen-
sions demonstrated that IFN-
 
 
 
 protein was expressed in
developing psoriatic skin lesions and was confined to
BDCA-2
 
 
 
 PDCs (Fig. 4). In contrast, IFN-
 
 
 
 was not de-
tectable in PDCs or other cells derived from uninvolved skin
(Fig. 4) or peripheral blood (unpublished data) of the same
psoriasis patient. These data indicate that PDCs represent the
principal IFN-
 
 
 
–producing cell in developing psoriasis.
 
Blocking of IFN-
 
 
 
/
 
 
 
 signaling inhibits the development 
of psoriasis
 
To further investigate the importance of PDC-derived IFN-
 
 
 
in the development of psoriasis, we sought to block IFN-
 
 
 
signaling in vivo during the spontaneous conversion of unin-
volved skin into psoriatic skin lesions in the AGR
 
 
 
/
 
 
 
 xe-
nograft model perviously described (36). Transplanted mice
were treated with either neutralizing antibodies to IFN-
 
 
 
/
 
 
 
receptor (38) or an isotype-matched control antibody, and
histological analyses of grafts were performed at day 35.
Whereas skin grafts from mice receiving the isotype-matched
Figure 3. Quantification of IFN-  and IRF-7 mRNA levels in 
primary plaque lesions and developing psoriasis. (a) Normalized IFN-  
and IRF-7 mRNA expression (fg/25 ng of total mRNA) in primary psoriatic 
plaque lesions compared with normal skin and measured by quantitative 
real-time RT-PCR. The increased IRF-7 mRNA expression levels in psoriatic 
skin lesions (n   24, mean   32.09) compared with normal skin (n   11, 
mean   5.026) were significant (P   0.0001, unpaired Student’s t  test). 
(b, top) Kinetics of normalized human IFN-  (gene copies per picogram of 
human mRNA) and IRF-7 (fg/10 pg of human mRNA) expression during 
psoriasis development in the AGR /  xenograft model. (b, bottom) Human 
CD3  T cells (open circles) and papillomatosis index (closed circles) during 
the development of psoriasis in the AGR /  model. The arrow indicates the 
onset of a psoriatic phenotype defined by the typical epidermal hyperplasia 
involving both an increase in papillomatosis and acanthosis (not depicted) 
indices. Data represent the mean of three independent experiments.
Figure 4. IFN-  production in developing psoriatic lesions is medi-
ated by PDCs. Flow cytometric analysis of surface BDCA-2 and intracellular 
IFN- 2 expression in dermal single cell suspensions derived from develop-
ing psoriatic lesions (across the margin zone of advancing psoriatic 
plaques) and uninvolved skin. In developing psoriatic lesions, intracellular 
IFN-  expression was detected among BDCA-2  PDCs but completely absent 
in dermal cells lacking BDCA-2, a cell fraction which mainly consists of T 
cells and myeloid APCs. Data are representative of three independent 
experiments. Percentages of positive cells are indicated in each quadrant. 
Differences in the percentages of PDCs positively stained for IFN-  in 
comparison with matched isotype control, as well as differences in the 
percentages of IFN- –expressing BDCA-2  PDCs compared with non-
PDCs, were significant (P   0.003, unpaired Student’s t test).JEM VOL. 202, July 4, 2005 139
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control antibodies developed into full-fledged psoriatic le-
sions, with T cell numbers and epidermal hyperplasia reaching
similar levels to those of primary psoriatic plaques of the graft
donor, treatment with neutralizing anti–IFN- /  receptor
antibody completely inhibited both the activation and expan-
sion of pathogenic T cells (Fig. 5 a) and the development of
the psoriatic phenotype (Fig. 5 b and Fig. S4, available at http:
//www.jem.org/cgi/content/full/jem.20050500/DC1). These
data indicate a requirement for IFN- /  signaling for the T
cell–dependent development of psoriasis.
PDC-derived IFN-  is essential for the development 
of psoriasis
Because we have demonstrated that PDCs are a principal
source of IFN-  in developing psoriatic lesions, we next
sought to determine whether psoriasis development was me-
diated by PDC-derived IFN- . For this purpose, we took
advantage of the anti–BDCA-2 monoclonal antibody that
specifically binds to human PDCs and suppresses their ability
to secrete IFN-  (29). Given that human cells derived from
the transplanted skin do not recirculate in the AGR /  mice
(36), in vivo treatment with anti–BDCA-2 selectively targets
human PDCs present in engrafted prepsoriatic skin. Intrave-
nous injection of anti–BDCA-2 antibody led to a  90% re-
duction of IFN-  expression in engrafted skin at day 13 after
transplantation (Fig. 6 a), confirming that PDCs represented
the principal IFN- –producing cells in the engrafted skin.
Anti–BDCA-2 antibody injections completely inhibited the
activation and expansion of pathogenic T cells and the de-
velopment of a psoriatic phenotype (Fig. 6, b and c; and Fig.
S5, available at http://www.jem.org/cgi/content/full/
jem.20050500/DC1). To test whether IFN-  was sufficient
to reverse the anti–BDCA-2–mediated inhibition of psoriasis
development, we administered recombinant human IFN- 
during anti–BDCA-2 antibody treatment. In contrast to the
anti–BDCA-2 treatment alone, the addition of IFN-  in-
duced a strong activation and expansion of pathogenic T
cells and the development of a full-fledged psoriatic plaque
lesion (Fig. 6, b–d), demonstrating that PDC-derived IFN- 
was not only necessary but also sufficient to drive psoriasis
development from prepsoriatic skin. In contrast, IFN-  was
not able to induce T cell expansion and psoriasis develop-
ment in normal skin transplanted onto AGR mice, suggest-
ing that factors already present in normal-appearing pre-
psoriatic skin are a prerequisite for the IFN- –mediated
induction of the pathogenic T cell cascade leading to psoria-
sis (Fig. 6, b and c).
DISCUSSION
Psoriasis is a Th1 cell–mediated autoimmune disease affecting
the skin of genetically predisposed individuals. In recent
years, there has been growing interest in the role of innate
immunity to explain the interplay between environmental
triggers and the exacerbation of the autoimmune T cell cas-
cade leading to psoriasis. We uncovered a key innate immune
pathway for triggering psoriasis. We show that PDCs accu-
mulate in the skin of psoriasis patients and become activated
to produce IFN-  early during disease development. Fur-
thermore, we demonstrate that, through the production of
IFN- , PDCs drive the activation and expansion of autoim-
mune T cells in prepsoriatic skin, leading to the development
of psoriasis. Thus, our findings revise the current immuno-
pathogenic understanding of psoriasis by identifying a key
proximal event based on the presence of PDCs in psoriatic
skin and their innate activation to produce IFN- .
PDCs represent a unique cell type in antiviral immunity
because of their unique ability to secrete large amounts
of IFN-  on viral stimulation through toll-like receptor
(TLR)-7 and TLR-9 (39, 40). PDCs have also been found
in the inflamed tissue of autoimmune diseases, including lu-
pus erythematosus (15), rheumatoid arthritis (41), and psori-
asis (17, 19), although a functional relevance had not been
demonstrated. We provide the first direct evidence that
PDCs play a key role in the elicitation of a common autoim-
mune disease. We show that PDCs are increased in the nor-
mal-appearing prepsoriatic skin of psoriasis patients com-
pared with the skin of healthy controls and demonstrate that
this accumulation represents a conditioning factor for future
flares of the disease. Through their ability to secrete IFN- 
in response to innate activation signals, PDCs in prepsoriatic
skin determine the onset of local autoimmune inflammation
leading to disease formation. Because injury to the skin is a
well known elicitation factor for psoriasis (42), PDC activa-
tion may result from the release of skin-derived products on
infectious or mechanical stress (simulated in the AGR / 
model by the transplantation procedure). In psoriatic skin,
Figure 5. IFN- /  signaling is required for the development of 
psoriatic skin lesions. Human CD3  T cell count (a) and papillomatosis 
index in skin grafts before transplantation (uninvolved prepsoriatic skin at 
day 0) and 35 d after transplantation subsequent to the administration of 
isotype-matched control Ab or neutralizing anti–IFN- /  receptor mAb 
(b). Values of primary psoriatic plaques derived from the graft donors are 
provided in comparison. Error bars in panel a represent one SD. Dots in 
panel b represent independently grafted mice or patient samples. p-values 
calculated by the unpaired Student’s t test are indicated.PLASMACYTOID PREDENDRITIC CELLS IN PSORIASIS | Nestle et al. 140
potential activation signals may include pathogen- or self-
derived single-stranded RNA, recently identified as potent
IFN-  inducers in PDCs through TLR-7 (43). Accordingly,
we have observed that psoriasis can be exacerbated by topical
application of imiquimod, a synthetic TLR-7 agonist (19).
Furthermore, it has been recently demonstrated that TLR-
mediated inflammation of the peripheral target organ is a
prerequisite for the conversion of T cell autoreactivity into
overt autoimmune disease (44).
Our study defines IFN-  as the molecular mediator of
PDC function in eliciting psoriasis. PDC-derived IFN- 
may drive the “quiescent” autoimmune T cells in prepsori-
atic skin into activated pathogenic effectors through the in-
duction of myeloid DC activation/maturation. An unabated
activation of myeloid DCs through IFN-  with the conse-
quent activation of autoimmune T cells has been recognized
as a key pathogenic event in SLE (13, 45). In line with these
findings, we have previously shown that myeloid DCs in
psoriatic skin are also activated and have the ability to stimu-
late autoimmune T cells (46). The presence of high levels of
lesional IFN-  might favor cross-presentation of sequestered
tissue-specific autoantigens by myeloid DCs (47). PDC-
derived IFN-  may also enhance the survival and expansion
of T cells through the induction of IL-15 (48) or may act di-
rectly on T cells by promoting their expression of T-bet and
IL12-R 2 (49), thus potentiating the Th1 cell bias of patho-
genic T cells in psoriasis.
Our data provides the direct evidence that IFN-  is a
master cytokine in psoriasis development. In contrast to
TNF- , a validated therapeutic target for psoriasis expressed
throughout psoriatic inflammation (36, 50–52), production
of IFN-  is a tightly regulated, transient event occurring
early during the development of psoriasis. Furthermore, in
contrast to the broad expression of TNF-  by a variety of
Figure 6. PDC-derived IFN-  is necessary and sufficient to drive 
the development of psoriatic skin lesions. (a) Normalized human IFN-  
mRNA expression in skin grafts harvested 13 d after transplantation sub-
sequent to the administration of isotype-control Ab or anti–BDCA-2 mAb. 
The mean plus one SD of two independent experiments is given. Human 
CD3  T cell count (b) and papillomatosis index (c) in skin grafts before 
transplantation (uninvolved skin at day 0) and 35 d after transplantation 
subsequent to the administration of isotype-matched control Ab, anti–
BDCA-2 mAb, or anti–BDCA-2 plus recombinant human IFN- . Dots rep-
resent independently grafted mice. In panel b, the mean of these experi-
ments plus one SD is given. p-values were calculated using the unpaired 
Student’s t test. As a control, normal skin (from healthy donors) was trans-
planted with or without systemic injections of recombinant human IFN- . 
(d) Histologic analysis of the skin grafts harvested at day 35 after trans-
plantation. The development of a psoriatic phenotype is inhibited by the 
administration of anti–BDCA-2 and fully restored by the addition of 
recombinant human IFN- . The dashed line indicates the border between 
the epidermis and the dermis.JEM VOL. 202, July 4, 2005 141
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cells, including myeloid DCs, T cells, and keratinocytes, the
production of IFN-  in psoriatic skin seems to be confined
to dermal PDCs. This may reflect the specialization of PDCs
to recognize distinct TLR ligands (39, 40), as well as their
extraordinary ability to produce large amounts of IFN- ,
because of a prolonged endosomal retention of TLR ligands
with consequent sustained MyD88/IRF-7 signaling (53).
We therefore propose a spatial and temporal view of psoriasis
development in which PDC-derived IFN-  represents an
early upstream event preceding autoimmune inflammation
and the development of psoriasis.
Increasing evidence indicates that IFN-  plays a pivotal
role in the pathogenesis of other autoimmune disorders such
as SLE, insulin-dependent diabetes mellitus (IDDM), and
rheumatoid arthritis (for review see reference 54). As for
psoriasis, IFN-  treatment for unrelated conditions can in-
duce or exacerbate these autoimmune diseases (55–57). Evi-
dence for a pathogenic role of IFN-  in SLE was provided
by the finding that SLE patients have increased serum levels
of IFN-  that coincide with exacerbations of the disease (58,
59). In addition, large numbers of PDCs are found in the
skin lesions of SLE and may be activated to produce IFN- 
by immune complexes consisting of anti–double-stranded
DNA antibodies and DNA derived from apoptotic cells (60).
Patients with IDDM demonstrate increased levels of IFN- 
in the serum and in the pancreas (61). In addition, convinc-
ing evidence for a role of IFN-  in the pathogenesis of
IDDM has been obtained from murine studies (44, 62).
IFN-  signature has also been detected in the synovium of
rheumatoid arthritis patients and has been correlated with
the infiltration and activation of PDCs (63). Thus, the or-
gan-specific accumulation of PDCs and their innate activa-
tion to produce IFN-  may represent a common proximal
pathway that drives the efferent arm of immune responses
leading to exacerbation of the underlying autoimmune dis-
eases in susceptible individuals.
In conclusion, this study identifies PDCs and PDC-
derived IFN-  as being important upstream initiators of
psoriasis development. Given the side effects and limitations
of current antipsoriatic therapies, including TNF-  blockers
for long term disease control (64), we propose that new
strategies targeting PDCs and PDC-derived IFN-  should
be considered both for prevention and early therapeutic in-
tervention in psoriasis and, potentially, other related autoim-
mune diseases.
MATERIALS AND METHODS
Tissue samples, immunohistochemistry, and confocal laser scan-
ning microscopy (CLSM) analysis. Human psoriasis studies were ap-
proved by the Institutional Review Board of the University Hospital of Zu-
rich. Biopsies from patients with stable plaque-type psoriasis were taken
after informed consent was obtained and diagnosis of psoriasis was histolog-
ically confirmed. Cryopreserved skin specimens were fixed in acetone, sub-
sequently stained with an excess of primary Ab, including anti–human
BDCA-2 mAb (Miltenyi Biotec), anti–human MxA (a gift of J. Pavlovic,
University of Zurich, Zurich, Switzerland), or IgG isotype control, and the
signals were amplified by sequential incubations with rabbit anti–mouse IgG
xenoantibodies and alkaline phosphatase–anti-alkaline phosphatase com-
plexes as previously described (36). The immunoreaction was visualized
with a developing solution containing neufuchsin (DakoCytomation) and
counterstained with 1% hematoxylin. For immunofluorescence analysis, ac-
etone-fixed cryopreserved specimens were stained with unlabeled anti–
BDCA-2 mAb followed by FITC-labeled anti–mouse IgG mAb (DakoCy-
tomation), anti-CD123 PE (BD Biosciences), and anti-CD3 APCs (BD
Biosciences) for 1 h each. Immunofluorescence was analyzed by CLSM
(DM IRB/E; Leica).
Isolation of dermal cells and flow cytometry analysis. Skin keratome
biopsies (20   20   0.4 mm) of plaque psoriasis lesions and uninvolved skin
(normal-appearing skin at a distance of  0.5 cm from the lesion) were taken
from the buttocks or upper thigh of patients with confirmed plaque-type
psoriasis as described previously (46). Patients did not receive topical or sys-
temic therapy for at least 4 wk before the study. For analysis of developing
psoriasis lesions, biopsies were taken across the margin zone (immediately in-
side and outside of the clinical edge) of spreading psoriatic lesions as defined
clinically (37). Dermal sheets were separated from epidermal sheets, cut into
small pieces (1–5 mm), and carefully enzymatically digested to yield single
cell suspensions as previously described (46). Three-color staining was per-
formed by using anti–BDCA-2 FITC, CD123 APCs (Miltenyi Biotech),
and PE-labeled CD3, CD4, CD11b, CD11c, CD14, CD20, CD56, CD80,
CD86, CD83, and HLA-DR (all obtained from Becton Dickinson) or their
corresponding isotype controls. For intracellular IFN-  detection, cells were
first surface stained with anti–BDCA-2 FITC, followed by permeabilization
and incubation with PE-labeled anti–human IFN- 2 mAb (Chromaprobe
Inc.) or IgG2b isotype control. Cells were analyzed using a flow cytometer
(FACSCalibur; Becton Dickinson) and data were processed using Cell-
QuestPro (Becton Dickinson).
Real-time quantitative PCR. Total RNA from homogenized skin spec-
imens was extracted and reverse transcribed as previously described (36).
Complementary DNA was quantitatively analyzed for the expression of
IFN-  and IRF-7 transcripts by real-time PCR using primers designed
against most human IFN-  sequences and against human IRF-7 (left, 5 -
TCCCCACGCTATACCATCTACCT-3 ; right, 5 -ACAGCCAGGGT-
TCCAGCTT-3 ; Applied Biosystems). 18S ribosomal RNA was used for
normalization. In the AGR model, IFN-  was quantified in transplanted
skin by using a primer kit recognizing most human IFN-  genes and that did
not recognize its mouse counterpart (Search-LC). Human GAPDH mRNA
levels were quantified using human-specific primers (left, 5 -ATTGCCCT-
CAACGACCACTTTG-3 ; right, 5 -TTGATGGTACATGAAAGGTG-
AGG-3 ) and used for normalization as previously described (36).
Animals and transplantation procedure. Animal studies were ap-
proved by the Kantonale Veterinaersamt of Zurich. AGR129 mice, defi-
cient in type I (A) and type II (G) IFN receptors, in addition to being
RAG-2 / , were kept pathogen free throughout the study. Keratomes of
uninvolved prepsoriatic or normal skin (a gift of S. Baldi, University Hospi-
tal of Zurich, Zurich Switzerland) as controls were transplanted to the back
of mice using an absorbable tissue seal as previously described (36). 35 d af-
ter engraftment, transplanted skin was removed and snap frozen for histo-
logical or mRNA expression analysis. CD3  T cell counts, acanthosis, and
papillomatosis index were determined histologically as previously described
(36). CD3  T cell values represent the mean cell count of three random
fields assessed at 400  by two independent investigators. The indicated
papillomatosis and acanthosis values represent the mean of 10 random areas
of each sample.
Neutralization studies. Dosage and schedule of antibody administration
were deduced based on previous data with anti–human mAbs against other
cell surface molecules (36) and administered as follows: (a) i.v. injection of
30  g neutralizing anti–human IFN- /  Receptor Chain 2 (CD118) mAb
(clone MMHAR-2; PBL Biomedical Laboratories) twice weekly for 35 d,PLASMACYTOID PREDENDRITIC CELLS IN PSORIASIS | Nestle et al. 142
starting at day 0 after transplantation; and (b) i.v. injection of 30  g anti–
BDCA-2 mAb (reference 29; provided by J. Schmitz, Miltenyi Biotec, Ber-
gisch-Gladbach, Germany) twice weekly for 35 d, starting at day 0 after
transplantation. For IFN-  reconstitution experiments, 30,000 IU recombi-
nant human IFN- 2a (Roferon A; Roche) were administered systemically
by s.c. injections three times a week for 35 d. Dosage corresponds to the
therapeutic dose of 8 Mio IU used in humans and was deduced by an allo-
metric approach as previously described (36).
Online supplemental material. Fig. S1 shows absent expression of
BDCA-2 in normal skin and atopic dermatitis skin. Fig. S2 shows plasmacy-
toid morphology and the classical phenotype of PDCs in psoriatic lesions.
Fig. S3 shows IFN-  activity in psoriatic plaque lesions but not the unin-
volved skin of psoriatic patients, normal skin of healthy individuals, or skin
lesions of atopic dermatitis patients. Figs. S4 and S5 show induction and in-
hibition of psoriasis development in the AGR model as measured by the
epidermal acanthosis index. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20050500/DC1.
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